Polypharmacy and bone fracture risk

Shih-Wei Lai^{1

2}, Bing-Fang Hwang³, Chiu-Shong Liu^{4

2}, Kuan-Fu Liao^{5

6}

Affiliations

¹ Department of Public Health, College of Public Health, and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
² Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan.
³ Department of Occupational Safety and Health, College of Public Health, China Medical University, Taichung, Taiwan.
⁴ School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
⁵ College of Medicine, Tzu Chi University, Hualien, Taiwan. kuanfuliaog@gmail.com.
⁶ Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, No. 66, Sec. 1, Fongsing Road, Tanzi District, Taichung City, 427, Taiwan. kuanfuliaog@gmail.com.

Comment

Shih-Wei Lai et al. J Bone Miner Metab. 2022 May.

. 2022 May;40(3):535-536.

doi: 10.1007/s00774-021-01307-1. Epub 2022 Feb 2.

Shih-Wei Lai^{1

2}, Bing-Fang Hwang³, Chiu-Shong Liu^{4

2}, Kuan-Fu Liao^{5

6}

¹ Department of Public Health, College of Public Health, and School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
² Department of Family Medicine, China Medical University Hospital, Taichung, Taiwan.
³ Department of Occupational Safety and Health, College of Public Health, China Medical University, Taichung, Taiwan.
⁴ School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
⁵ College of Medicine, Tzu Chi University, Hualien, Taiwan. kuanfuliaog@gmail.com.
⁶ Division of Hepatogastroenterology, Department of Internal Medicine, Taichung Tzu Chi Hospital, No. 66, Sec. 1, Fongsing Road, Tanzi District, Taichung City, 427, Taiwan. kuanfuliaog@gmail.com.

No abstract available

Comment in

Authors' reply.
Wakasugi M, Yokoseki A, Wada M, Momotsu T, Sato K, Kawashima H, Nakamura K, Onodera O, Narita I. Wakasugi M, et al. J Bone Miner Metab. 2022 May;40(3):537-538. doi: 10.1007/s00774-022-01315-9. Epub 2022 Feb 20. J Bone Miner Metab. 2022. PMID: 35184207 No abstract available.

Polypharmacy, chronic kidney disease, and incident fragility fracture: a prospective cohort study.
Wakasugi M, Yokoseki A, Wada M, Momotsu T, Sato K, Kawashima H, Nakamura K, Onodera O, Narita I. Wakasugi M, et al. J Bone Miner Metab. 2022 Jan;40(1):157-166. doi: 10.1007/s00774-021-01272-9. Epub 2021 Nov 3. J Bone Miner Metab. 2022. PMID: 34729651

1. Wakasugi M, Yokoseki A, Wada M, Momotsu T, Sato K, Kawashima H, et al (2021) Polypharmacy, chronic kidney disease, and incident fragility fracture: a prospective cohort study. J Bone Miner Metab
1. Komorita Y, Ohkuma T, Iwase M, Fujii H, Oku Y et al (2021) Polypharmacy and bone fracture risk in patients with type 2 diabetes: the Fukuoka Diabetes Registry. Diabetes Res Clin Pract 181:109097 - DOI
1. Tran T, Bliuc D, Hansen L, Abrahamsen B, van den Bergh J et al (2018) Persistence of excess mortality following individual nonhip fractures: a relative survival analysis. J Clin Endocrinol Metab 103:3205–3214 - DOI
1. Koseki H, Sunagawa S, Noguchi C, Yonekura A, Matsumura U et al (2021) Incidence of and risk factors for hip fracture in Nagasaki, Japan from 2005 to 2014. Arch Osteoporos 16:111 - DOI
1. Lai SW, Liao KF, Liao CC, Muo CH, Liu CS, Sung FC (2010) Polypharmacy correlates with increased risk for hip fracture in the elderly: a population-based study. Medicine 89:295–299 - DOI